The burgeoning popularity of semaglutide , initially for metabolic conditions, is creating significant attention within the British Isles, prompting a notable shift in hormone trends. Access these medications remains a complex landscape, with National Health Service coverage currently limited and specialist practices offering therapy at a higher co